Ask AI
ASH25 Multiple Myeloma

CE / CME

Emerging Data and Clinical Implications in Multiple Myeloma: ASH 2025 Highlights

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Released: March 05, 2026

Expiration: September 04, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Mateos MV, Bahlis N, Perrot A, et al. Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3ASH 2025. Presented at: 2025 Annual Meeting of the American Society of Hematology. Abstr LBA6.
  2. Costa LJ, Bahlis NJ, Perrot A, et al. Teclistamab plus daratumumab in relapsed or refractory multiple myeloma. N Engl J Med. 2025;[Epub ahead of print].
  3. Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373:1207-1219.
  4. Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128:384-394.
  5. Usmani S, Kumar S, Mateos MV, et al. Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: updated phase 2 results from the redirectt-1 study with extended follow-up. Presented at: 2025 Annual Meeting of the American Society of Hematology. Abstr 698.
  6. Kumar S, Mateos MV, Ye JC, et al. Dual targeting of extramedullary myeloma with talquetamab and teclistamab. N Engl J Med. 2026;394:51-61.
  7. Moreau P, Mateos MV, Goldschmidt H, et al. Outcomes of patients with extramedullary disease in triple-class exposed relapsed/refractory multiple myeloma from the pooled LocoMMotion and MoMMent studies. Clin Lymphoma Myeloma Leuk. 2025;25:646-655.e1.
  8. Ho M, Paruzzo L, Minehart J, et al. Extramedullary multiple myeloma: challenges and opportunities. Curr Oncol. 2025;32:182.
  9. Cohen YC, Magen H, Gatt M, et al. Talquetamab plus teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2025;392:138-149.
  10. Kumar S, Mateos MV, Ye JC, et al. Dual targeting of extramedullary myeloma with talquetamab and teclistamab. N Engl J Med. 2026;394:51-61.
  11. Harrison S, Riley CH, Mian H, et al. Tumor clearance, T-cell fitness, and minimal residual disease (MRD) outcomes in patients with relapsed/refractory multiple myeloma (RRMM) treated with cevostamab plus pomalidomide and dexamethasone: Biomarker analyses from CAMMA 1 Arm B. ASH 2025. Presented at: 2025 Annual Meeting of the American Society of Hematology. Abstr 252.
  12. Jiang D, Huang H, Qin H, et al. Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma. Nat Commun. 2023;14:3642.
  13. Richter J, Thomas SK, Krishnan AY, et al. Cevostamab in patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study demonstrate clinically meaningful activity and manageable safety and inform the doses and regimen for combination studies. Presented at: 2024 Annual Meeting of the American Society of Hematology. Abstr 1021.
  14. Ho PJ, Quach H, Delimpasi S, et al. Subcutaneous cevostamab demonstrates manageable safety and clinically meaningful activity in Relapsed/Refractory multiple myeloma (RRMM): First results from the Phase Ib CAMMA 3 study. Presented at the 2025 Annual Meeting of the American Society of Hematology. Abstr 700.
  15. Di Palma-Grisi J, Siegel D, Biran N, et al. Pomalidomide salvage in T-cell engager monotherapy failures: Real-world experience with talquetamab or elranatamab with pomalidomide combinations in heavily pretreated multiple myeloma. Presented at: 2025 Annual Meeting of the American Society of Hematology. Abstr 2229.
  16. Cohen A, Susanibar-Adaniya S, Garfall A, et al. Phase 2 study of cevostamab consolidation following BCMA CAR T cell therapy:  preliminary safety, efficacy, and correlative data from the “STEM” (Sequential T Cell-Engagement for Myeloma) trial. Presented at: 2025 Annual Meeting of the American Society of Hematology. Abstr 699.
  17. San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389:335-347.
  18. Perica K, Nataraj S, Lemdal Sjojstrand M, et al. Low target antigen expression mediates resistance to BCMA CAR T cell therapy. Presented at: 2023 Annual Meeting of the American Society of Hematology. Abstr 2124.
  19. Costa L, Oriol A, Dytfeld D, et al. Long-term progression-free survival benefit with ciltacabtagene autoleucel in standard-risk relapsed/refractory multiple myeloma. Presented at: 2025 Annual Meeting of the American Society of Hematology. Abstr 94.
  20. Jagannath S, Martin TG, Lin Y, et al. Long-term (≥5-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed/refractory multiple myeloma. J Clin Oncol. 2025;43:2766-2771.
  21. San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389:335-347.
  22. Costa LJ, Weisel KC, van de Donk NWCJ, et al. Ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis. Presented at: 2024 American Society of Clinical Oncology Annual Meeting. Abstr 7504.
  23. Patel K, Dhakal B, Kaur G, et al. Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Updated results from iMMagine-1. Presented at: 2025 Annual Meeting of the American Society of Hematology. Abstr 256.
  24. Frigault MJ, Bishop MR, Rosenblatt J, et al. Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. Blood Adv. 2023;7:768-777.
  25. Freeman CL, Dhakal B, Kaur G, et al. Phase 2 registrational study of antiocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: preliminary results from the IMMagine-1 trial. Presented at: 2024 Annual Meeting of the American Society of Hematology. Abstr 1031.
  26. Hansen DK, Peres LC, Dima D, et al. Comparison of standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed/refractory multiple myeloma. J Clin Oncol. 2025;43:1597-1609.
  27. Richard S, Gaballa M, Gregory T, et al. Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary Results from the DURGA-1 Phase 1b/2 study. Presented at: 2025 Annual Meeting of the American Society of Hematology. Abstr 269.
  28. Steinhardt MJ, Einsele H, Waldschmidt JM. Advances in CD19-targeting CAR-T cell therapies for multiple myeloma. Expert Opin Biol Ther. 2025;25:21-25.
  29. Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388:1002-1014.
  30. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398:314-324.
  31. Du J, Qiang W, Lu J, et al. A phase I open-label single-arm study of dual targeting BCMA and CD19 FasTCAR-T (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma. Presented at: 2024 Congress of the European Hematology Association. Abstr S200.
  32. Du J, Fu WJ, Jiang H, et al. Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). Presented at: 2023 Annual Meeting of the American Society of Clinical Oncology. Abstr 8005.